JP2015519401A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519401A5
JP2015519401A5 JP2015517370A JP2015517370A JP2015519401A5 JP 2015519401 A5 JP2015519401 A5 JP 2015519401A5 JP 2015517370 A JP2015517370 A JP 2015517370A JP 2015517370 A JP2015517370 A JP 2015517370A JP 2015519401 A5 JP2015519401 A5 JP 2015519401A5
Authority
JP
Japan
Prior art keywords
amino
pyrimidin
carbonyl
pyrazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517370A
Other languages
English (en)
Japanese (ja)
Other versions
JP6189945B2 (ja
JP2015519401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/045266 external-priority patent/WO2013191965A1/en
Publication of JP2015519401A publication Critical patent/JP2015519401A/ja
Publication of JP2015519401A5 publication Critical patent/JP2015519401A5/ja
Application granted granted Critical
Publication of JP6189945B2 publication Critical patent/JP6189945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517370A 2012-06-18 2013-06-11 癌および自己免疫疾患の治療に有用な可逆性共有結合ピロロ−またはピラゾロピリミジン Active JP6189945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661203P 2012-06-18 2012-06-18
US61/661,203 2012-06-18
PCT/US2013/045266 WO2013191965A1 (en) 2012-06-18 2013-06-11 Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2015519401A JP2015519401A (ja) 2015-07-09
JP2015519401A5 true JP2015519401A5 (enExample) 2016-08-04
JP6189945B2 JP6189945B2 (ja) 2017-08-30

Family

ID=48692669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517370A Active JP6189945B2 (ja) 2012-06-18 2013-06-11 癌および自己免疫疾患の治療に有用な可逆性共有結合ピロロ−またはピラゾロピリミジン

Country Status (11)

Country Link
US (1) US20160045503A1 (enExample)
EP (1) EP2861599B1 (enExample)
JP (1) JP6189945B2 (enExample)
KR (1) KR102150432B1 (enExample)
CN (1) CN104487441B (enExample)
AU (1) AU2013277582B2 (enExample)
CA (1) CA2874461C (enExample)
DK (1) DK2861599T3 (enExample)
ES (1) ES2776175T3 (enExample)
MX (1) MX368112B (enExample)
WO (1) WO2013191965A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PH12014500122A1 (en) 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
PL2892900T3 (pl) 2012-09-10 2018-02-28 Principia Biopharma Inc. Związki pyrazolopirymidonowe jako inhibitory kinazy
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP2016531941A (ja) 2013-09-30 2016-10-13 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CN106456642A (zh) 2014-03-12 2017-02-22 诺华股份有限公司 含btk抑制剂与akt抑制剂的组合
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP3193877A4 (en) 2014-08-07 2018-04-04 Pharmacyclics LLC Novel formulations of a bruton's tyrosine kinase inhibitor
US10196397B2 (en) 2014-11-19 2019-02-05 Sun Pharmaceutical Industries Limited Process for the preparation of ibrutinib
US10485797B2 (en) * 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
IL252913B (en) * 2014-12-24 2022-06-01 Principia Biopharma Inc Dose of site-specific btk inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
WO2016154998A1 (zh) * 2015-04-03 2016-10-06 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
SI3303334T1 (sl) * 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
EP4116303A1 (en) 2015-09-16 2023-01-11 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EP3782994B1 (en) 2015-12-16 2025-07-16 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CN111153906B (zh) * 2016-05-16 2020-09-11 苏州信诺维医药科技有限公司 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
MX390619B (es) 2016-06-29 2025-03-21 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN110483521B (zh) * 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
KR102300092B1 (ko) * 2018-11-05 2021-09-09 가톨릭대학교 산학협력단 pH 민감성 탄소 나노입자, 이의 제조방법 및 이를 이용한 약물전달
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药(上海)有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2020263822A1 (en) 2019-06-25 2020-12-30 San Diego State University Foundation Selective btk irreversible inhibitors
WO2021029467A1 (en) * 2019-08-14 2021-02-18 Sam Chun Dang Pharm. Co., Ltd. A solid dosage form for orally administration
CN110448557A (zh) * 2019-09-05 2019-11-15 黄筱茜 抗凝血药达比加群酯的新药用途
MX2022004427A (es) 2019-10-14 2022-07-12 Principia Biopharma Inc Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
US11583533B2 (en) 2020-01-08 2023-02-21 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
MX2022008875A (es) 2020-01-20 2022-08-11 Genzyme Corp Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
JP2023545414A (ja) * 2020-10-05 2023-10-30 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Her2の強力かつ選択的な阻害剤
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
CN116669770A (zh) * 2020-12-23 2023-08-29 耶达研究与发展有限公司 甲基丙烯酰胺蛋白质结合剂及其用途
KR102806844B1 (ko) * 2022-06-03 2025-05-16 주식회사 서흥 장용성 경질캡슐의 제조를 위한 밴딩 용액과 이를 이용하여 제조한 장용성 경질캡슐
EP4540226A1 (en) * 2022-06-16 2025-04-23 Amphista Therapeutics Ltd Bifunctional molecules for targeted protein degradation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
MX2012005678A (es) 2009-11-16 2012-09-07 Univ California Enhibidores de cinasas.
SI2710005T1 (sl) * 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
DK2710007T3 (da) * 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere

Similar Documents

Publication Publication Date Title
JP2015519401A5 (enExample)
ES3036330T3 (en) Imidazopyridazines as modulators of il-17
ES2759775T3 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis B
CN110511209B (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN108738320B (zh) 用于治疗心血管疾病的cGMP调节剂
EP3312182B1 (en) Brk inhibitory compound
JP6218260B2 (ja) Jak阻害剤としてのアミノピリミジニル化合物
CN105732636B (zh) 杂芳化合物及其在药物中的应用
ES2871524T3 (es) Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
ES2651843T3 (es) Derivados de pirazolopirrolidina y su uso en el tratamiento de enfermedades
ES2745819T3 (es) Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
RU2017106742A (ru) Комбинированная терапия для лечения парамиксовируса
JP2012501312A5 (enExample)
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
KR20230159419A (ko) Tyk2 억제제 및 이의 용도
SI2892900T1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
RS54761B1 (sr) Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
JP2010500414A5 (enExample)
JP2014531449A5 (enExample)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
CN107667092A (zh) 作为fgfr4抑制剂的甲酰化n‑杂环衍生物
JP2016537384A5 (enExample)
CN114222741A (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物